Kathryn S Roberts

US Patent:

6531646, Mar 11, 2003

Filed:

Jun 12, 2000

Appl. No.:

09/581371

Inventors:

Donald P. Cheney - Ipswich MA
Kathryn M. Roberts - Melrose MA
Katherine L. Watson - Dover NH

Assignee:

Northeastern University - Boston MA

International Classification:

C12N 1505

US Classification:

800277, 800295, 800296, 800292, 435421, 435420, 435419, 435430, 435410, 435440, 435449, 435450, 435453, 435454

Abstract:

A method for the genetic modification and improvement of Porphyra species utilizing protoplast fusion is disclosed. The method of the invention features the use of conchoporangial branch conchocelis for at least one of the sources of protoplasts for protoplast fusion. Protoplasts produced from conchosporangial branch conchocelis of one species may be mixed with protoplasts produced from either blade material or conchocelis of a second species and fused using either a chemical fusing agent like polyethylene glycol (PEG) or electrofusion. Alternatively, an algal species other than a Porphyra species may be the second source of protoplasts. After fusion has occurred, fusion products are isolated and regenerated to whole plants or used as multicellular material. Because diploid conchocelis material is used as a source of protoplasts for at least one of the parents, regenerants can be produced that have stable, heritable, new genetic compositions, including hybrid, polyploid and aneuploid genomes, useful for strain improvement in the genus Porphyra.

US Patent:

8143311, Mar 27, 2012

Filed:

May 14, 2009

Appl. No.:

12/454202

Inventors:

Kathryn Roberts - Fairfield CT, US
Randall L. Carpenter - Boston MA, US
Mark F. Bear - Boston MA, US

Assignee:

Seaside Therapeutics, Inc. - Cambridge MA

International Classification:

A61K 31/195

US Classification:

514567

Abstract:

Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. Subjects having fragile X syndrome are treated with M1 muscarinic receptor antagonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. GABA(B) agonists can be used in combination with Group I mGluR antagonists and M1 muscarinic receptor antagonists in methods of treating humans.

US Patent:

8273715, Sep 25, 2012

Filed:

Jan 31, 2012

Appl. No.:

13/362656

Inventors:

Kathryn Roberts - Fairfield CT, US
Randall L. Carpenter - Boston MA, US
Mark F. Bear - Boston MA, US

Assignee:

Seaside Therapeutics, Inc. - Cambridge MA

International Classification:

A61K 38/00
A61K 31/197
A61K 31/195

US Classification:

514 181, 514 1, 514 177, 514567, 424 91

Abstract:

Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen.

US Patent:

8278276, Oct 2, 2012

Filed:

Jan 31, 2012

Appl. No.:

13/362985

Inventors:

Kathryn Roberts - Fairfield CT, US
Randall L. Carpenter - Boston MA, US
Mark F. Bear - Boston MA, US

Assignee:

Seaside Therapeutics, Inc. - Cambridge MA

International Classification:

A61K 38/00
A61K 31/197
A61K 31/195

US Classification:

514 181, 514 1, 514 177, 514567, 424 91

Abstract:

Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen.

US Patent:

20130012586, Jan 10, 2013

Filed:

Sep 13, 2012

Appl. No.:

13/614283

Inventors:

Kathryn Roberts - Fairfield CT, US
Randall L. Carpenter - Boston MA, US
Mark F. Bear - Boston MA, US

Assignee:

Seaside Therapeutics, Inc. - Cambridge MA

International Classification:

A61K 31/197
A61P 25/00

US Classification:

514567

Abstract:

Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen.

US Patent:

20130012587, Jan 10, 2013

Filed:

Sep 13, 2012

Appl. No.:

13/614715

Inventors:

Kathryn Roberts - Fairfield CT, US
Randall L. Carpenter - Boston MA, US
Mark F. Bear - Boston MA, US

Assignee:

Seaside Therapeutics, Inc. - Cambridge MA

International Classification:

A61K 31/197
A61P 25/00

US Classification:

514567

Abstract:

Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen.